Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Indaptus Therapeutics ( (INDP) ).
On September 4, 2025, Indaptus Therapeutics announced updates from its INDP-D101 clinical trial, highlighting the partial response in a patient with urothelial cancer using Decoy20 monotherapy, although disease progression was later observed. The company also reported on the safety of Decoy20 in combination with the PD-1 inhibitor tislelizumab, with mixed results among the initial cohort. Financially, Indaptus strengthened its balance sheet by converting $5.7 million in promissory notes into common stock, supporting its ongoing clinical efforts.
The most recent analyst rating on (INDP) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Indaptus Therapeutics stock, see the INDP Stock Forecast page.
Spark’s Take on INDP Stock
According to Spark, TipRanks’ AI Analyst, INDP is a Underperform.
Indaptus Therapeutics is facing considerable financial and operational difficulties, as highlighted by its poor financial performance with no revenue and continuous losses. The technical analysis further supports a negative outlook, with indicators pointing to bearish momentum. The company’s valuation is unattractive due to its unprofitability and lack of dividends. Collectively, these factors suggest a high-risk investment with limited short-term upside potential.
To see Spark’s full report on INDP stock, click here.
More about Indaptus Therapeutics
Indaptus Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and viral infections. The company utilizes a patented technology involving attenuated and killed Gram-negative bacteria to activate immune responses, aiming to provide a multi-targeted immune system activation with reduced intravenous toxicity.
Average Trading Volume: 233,100
Technical Sentiment Signal: Sell
Current Market Cap: $6.81M
For an in-depth examination of INDP stock, go to TipRanks’ Overview page.